Scientists identify bemnifosbuvir as potential hepatitis E treatment
Scientists have found that bemnifosbuvir, a drug in trials for hepatitis C, can block hepatitis E replication. This discovery could lead to a new treatment option for the virus, which currently lacks approved therapies. The findings emerge as hepatitis E causes tens of thousands of deaths annually.
Drug Mechanism and Trials
Bemnifosbuvir, currently under trial for hepatitis C, has shown promise in blocking the replication of hepatitis E by disrupting its genetic machinery. Laboratory tests conducted on cells and animals demonstrated the drug's ability to effectively inhibit the virus without damaging healthy tissue. The trials are being closely monitored by researchers aiming to repurpose the drug for hepatitis E treatment.
Impact on Hepatitis E
Hepatitis E, a virus responsible for tens of thousands of deaths annually, currently lacks an approved treatment. The identification of bemnifosbuvir as a potential therapeutic option marks a significant development in the fight against the virus. Researchers from multiple institutions are collaborating to expedite the drug's repurposing process, given its potential impact on global health.
What's Next
Ongoing trials will determine the drug's efficacy for hepatitis E treatment. It remains uncertain how soon the drug could be approved for this new use.
1 source
Scientists identify bemnifosbuvir as potential hepatitis E treatment
